Hungary: A New Model of Care
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
The OEP, as a central agency, performs the functions set out in legislation, carries out the tasks relating to the management of the National Health Insurance Fund, the maintenance of records, keeping financial accounts and fulfilling the reporting obligation.
The National Health Insurance Fund is supervised by the Government of Hungary, the central official organ of health insurance is managed by the Government through the Minister of Human Resources.
Healthcare services funded by the National Health Insurance Fund
Benefits in kind and cash benefits are provided by the OEP to the insured persons.
Benefits in kind includes cost-free healthcare services such as preventive examinations, primary healthcare, specialised inpatient care, specialised outpatient care, certain dental care, rehabilitation, the ambulance service, patient transport and accident-related benefits, drug reimbursement, reimbursement for medical aids, medical spa services, reimbursement of travel expenses and benefits granted on grounds of equity.
Cash benefits provided by the OEP include sickness benefit, prenatal allowance, child care fee and accident-related benefits.
The OEP has contractual relations with the healthcare providers. Investment and development costs of healthcare institutions are not covered by the Health Insurance Fund budget. The funding of these institutions is provided by their owners.
Contact
H – 1139 Budapest, Váci út 73/A.
Telefon: (+36-1) 350-2001
Fax: (+36-1) 298-2403
E-mail: oep@oep.hu
www.oep.hu
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Hungary operates under a state-owned universal National Health Insurance Fund (OEP), completely financed through mandatory tax contributions from employers and employees. “From a drug reimbursement point of view, we have…
Hungarian collector and producer of blood plasma and plasma-derived therapies HUMAN BioPlazma is rooted in over 60 years of history within the country, but only in 2008, with the influence…
While pharmaceutical products and healthcare financing dominate the majority of discussions surrounding the improvement of health outcomes, health literacy still remains a core issue that, if left unaddressed, may vary…
Preventive healthcare and health literacy are core issues in Hungary that, if left unaddressed, may hinder the country’s ability to push its health agenda forward and create a more sustainable…
Smaller pharma companies in Hungary are looking to new unconventional methods of OTC promotion to sidestep the country’s somewhat restrictive reimbursement scheme and compete with major players in the market. Especially in…
The President of the Doctoral Council of Semmelweis University, Dr. József Timár provides an overview of the healthcare system in Hungary with particular reference to oncology and describes the challenges…
LEO Pharma Hungary’s Andrea Bondár demonstrates the significance of adopting non-traditional methods of promotional activities, and defines how a true intent on understanding the psyche of patients suffering from chronic…
Anita Ordog, GM of Angelini Hungary, discusses the affiliate’s history in the country, their expanding OTC and specialty products portfolio, targeted marketing and sales strategies, and Angelini’s challenging entrance into…
Dr. Lívia Ilku, director of Hungary’s main domestic pharmaceutical manufacturers’ association (MAGYOSZ), describes the current priorities of its member companies and the key factors for success in Hungary; specifically innovation…
Prof. Dr. István Vályi-Nagy, Director General of the United St. Istvan and St. Laszlo Hospitals, shares his insights on running one of the largest hospitals in Hungary and the challenges…
The Managing Director of HUMAN BioPlazma, Ákos Tóth, highlights the transformational growth that the business has experienced since becoming a part of Kedrion Biopharma in 2008, while pinpointing the strategic…
See our Cookie Privacy Policy Here
